Abstract: A chip preparation method and system, and a chip are provided. The method includes: preparing, by using a laser direct writing exposure manner, a first underlying circuit of an impedance Josephson parametric amplifier and a second underlying circuit for testing, to obtain a first chip product; generating, on the first chip product by using the laser direct writing exposure manner, a photoresist structure for preparing a Josephson junction; cutting, from the first chip product, a second chip product on which the second underlying circuit is located and a third chip product on which the first underlying circuit is located; preparing a Josephson junction sample based on a photoresist structure corresponding to the second underlying circuit, to obtain an oxidation condition; and preparing, according to the oxidation condition, the Josephson junction based on a photoresist structure corresponding to the first underlying circuit.

Abstract: Devices for heating graphite for a vacuum sintering furnace are disclosed. In some examples, the device includes a heating unit. The heating unit includes a heating conductive strip, a fixing conductive block, a connecting conductive strip, and an isolating column. The plurality of heating conductive strips are connected end-to-end through the fixing conductive block to form a closed frame. One end of the connecting conductive strip is fixedly connected to one of the fixing conductive blocks, and the other end thereof is a free end. One of the two heating conductive strips communicated with the fixing conductive block provided with the connecting conductive strip is connected to the fixing conductive block through the isolating column. The plurality of heating units are disclosed. The heating conductive strips of the plurality of heating units connected to the isolating column are electrically connected through the connecting heating block.

Abstract: A therapeutic method for myocardial repair, includes providing a therapeutic needle, introducing the treatment needle to pierce from an epicardium into the myocardium without passing through an endocardium, and injecting therapeutant for myocardial repair through the treatment needle.

Abstract: A therapeutic device, therapeutic system and therapeutic method for myocardium repair, wherein the therapeutic device comprises a treatment needle for piercing the heart to release a therapeutant. The treatment needle includes a needle body (5a), the interior of the needle body (5) has a therapeutant conveying cavity, an end of the needle body (5a) is a needle (5b) which can pierce the myocardium and guide the needle body (5a) to pass through the myocardium, and the needle (5b) has a therapeutant output port which is connected to the therapeutant conveying cavity. The therapeutic device enters into the myocardium in a minimally invasive manner to release the therapeutant to the vicinity of the lesion to improve myocardial function or activity and prevent further deterioration of the disease.

Abstract: A bioretention pond includes a pond body and an overflow weir. The pond body includes a pond wall and a layered substrate. The layered substrate includes from bottom to top: a gravel layer, a transition layer, a pyrite layer, a plant layer, a pebble water layer, an organic layer, and a water storage layer. The overflow weir is disposed on the pebble water layer with a space left above the center of the pebble layer. The organic layer is disposed in the space and covers the pebble layer. The water storage layer is disposed onto the organic layer. The pond body further includes a perforated pipe disposed in the gravel layer; and the perforated pipe includes an outlet end disposed at the top part of the pyrite layer.

Abstract: The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt?-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.

Abstract: The use of a Wnt inhibitor Wnt-C59 in the preparation of a drug for treating SCN5A mutation-induced dilated cardiomyopathy (DCM) is provided. With SCN5A genotype detection as a breakthrough point, a Wnt pathway-specific inhibitor Wnt-C59 is used to inhibit the abnormal activation of the Wnt?-Catenin pathway caused by SCN5A gene mutation, thereby improving the prognosis of cardiac function in a patient with SCN5A gene mutation-induced DCM. In experiments, aging and adriamycin-induced DCM models are constructed, and the therapeutic effect of Wnt-C59 on DCM is detected through indexes such as changes in cardiac function and activation of related signal molecules, which provides a theoretical basis for use of Wnt-C59 in the clinical treatment of DCM. A new treatment method for SCN5A mutation-induced DCM is provided to bring dawn to such patients and has promising application prospects.

Abstract: An adsorption head includes a body. The body is a hollow housing, one side of the housing to which an adsorbed object is adsorbed is provided with an opening. The body comprises at least one adsorption chamber and at least one operation chamber therein, wherein the operation chamber and the adsorption chamber are spaced from each other and each have an opening orientated to the adsorbed object. The body has at least one adsorption passage and at least one operation passage thereon, wherein one end of the adsorption passage is communicated with the adsorption chamber, and one end of the operation passage is communicated with the operation chamber.

Abstract: An information interception method, a terminal, and a computer storage medium are disclosed.

Abstract: A therapeutic device, therapeutic system and therapeutic method for myocardium repair, wherein the therapeutic device comprises a treatment needle for piercing the heart to release a therapeutant. The treatment needle includes a needle body (5a), the interior of the needle body (5) has a therapeutant conveying cavity, an end of the needle body (5a) is a needle (5b) which can pierce the myocardium and guide the needle body (5a) to pass through the myocardium, and the needle (5b) has a therapeutant output port which is connected to the therapeutant conveying cavity. The therapeutic device enters into the myocardium in a minimally invasive manner to release the therapeutant to the vicinity of the lesion to improve myocardial function or activity and prevent further deterioration of the disease.

Abstract: An information interception method, a terminal, and a computer storage medium are disclosed.

Abstract: An information interception method, a terminal, and a computer storage medium are disclosed.

Abstract: An information interception method, a terminal, and a computer storage medium are disclosed.

Abstract: Disclosed is an anticoagulant polypeptide and applications thereof. The anticoagulant polypeptide comprises a polypeptide formed by an amino acid sequence as represented in Seq. ID No. 1; or comprises a derived polypeptide that selectively inhibits coagulation factor XIa and is formed by an amino acid sequence, as represented in Seq. ID No. 1, that has undergone one or multiple amino acid residue substitutions, deletions, or insertions. The anticoagulant polypeptide is a selective inhibitor for coagulation factor XIa, has anticoagulant activity and small side-effect, and can be used in preparing medicines for the prevention and treatment of thrombotic diseases.

Abstract: Disclosed is an anticoagulant polypeptide and applications thereof. The anticoagulant polypeptide comprises a polypeptide formed by an amino acid sequence as represented in Seq. ID No. 1; or comprises a derived polypeptide that selectively inhibits coagulation factor XIa and is formed by an amino acid sequence, as represented in Seq. ID No. 1, that has undergone one or multiple amino acid residue substitutions, deletions, or insertions. The anticoagulant polypeptide is a selective inhibitor for coagulation factor XIa, has anticoagulant activity and small side-effect, and can be used in preparing medicines for the prevention and treatment of thrombotic diseases.

Abstract: A method of providing a value for each element of a sequence of elements in a converter, the values being for a present conversion cycle in operation of the converter, wherein a pointer position identifies an element in the sequence of elements for a conversion cycle.

Abstract: A method of providing a value for each element of a sequence of elements in a converter, the values being for a present conversion cycle in operation of the converter, wherein a pointer position identifies an element in the sequence of elements for a conversion cycle.